V. Hersberger

Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.

J. Jassem, A. Wardley, X. Pivot, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.

J. Baselga, D. Miles, D. Cameron, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.